Manual of Mental Disorders

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Arthritis Drug

Arthritis Drug

U.S. approves Novartis drug Ilaris to treat childhood arthritis  Full Article 

Dementia & Longevity

Dementia & Longevity

Could family longevity protect against dementia?  Full Article 

Obamacare Expansion

Obamacare Expansion

Kentucky governor announces Medicaid expansion under Obamacare  Full Article 

Gum Stopped

Gum Stopped

Wrigley halts production of caffeine gum following FDA concern  Full Article 

Premature Babies

Premature Babies

Could vaginal delivery be safer for preemies?  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Pfizer Prevnar vaccine wins approval for ages 6-17

Related Topics

Stocks

   

Sat Jan 26, 2013 3:41am IST

(Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.

The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years. It is also approved for adults aged 50 and older.

The vaccine protects against infection with 13 strains of the Streptococcus pneumoniae bacterium. The bacterium can cause pneumonia, ear infections and other problems.

Prevnar 13 has annual sales of about $3.5 billion, making it Pfizer's third-biggest brand. It was approved in 2010, and has largely displaced an older vaccine called Prevnar, which protected against only 7 prevalent strains of the bacterium.

(Reporting by Ransdell Pierson; Editing by David Gregorio and Dan Grebler)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.